Skip to main content
. Author manuscript; available in PMC: 2014 Oct 1.
Published in final edited form as: Clin Lymphoma Myeloma Leuk. 2013 Jun 20;13(5):592–596. doi: 10.1016/j.clml.2013.05.004

Figure 1. Pooled analysis of decitabine response rates in patients with RAEB-t and in patients with myelodysplastic syndromes (MDS).

Figure 1

Significant differences in response rates between the RAEB-t and MDS groups were observed only for complete response (P = .028).

CR, complete response; HI, hematologic improvement; mCR, marrow complete response; OIR, overall improvement rate; ORR, overall response rate; PD, progressive disease; PR, partial response; RAEB-t, refractory anemia with excess of blasts in transformation; SD, stable disease.